Viral miniproteins

Annual Review of Microbiology

Volumn 68, Issue , 2014, Pages 21-43

  Dimaio, Daniel ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hydrophobic; Randomized library; Transmembrane protein; Traptamer; Viroporin

Indexed keywords

E5 PROTEIN; MEMBRANE PROTEIN; PROTEIN M2; SHORT HYDROPHOBIC PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VPU PROTEIN;

ANIMAL VIRUS; BIOLOGICAL ACTIVITY; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; FIBROPAPILLOMA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA VIRUS; NONHUMAN; PAPILLOMA VIRUS; PARAMYXOVIRUS; POXVIRUS; REVIEW; VIRUS GENOME; ANIMAL; CHEMISTRY; GENETICS; HUMAN; METABOLISM; VIROLOGY; VIRUS; VIRUS INFECTION;

ANIMALS; HUMANS; VIRAL PROTEINS; VIRUS DISEASES; VIRUSES;

EID: 84899878316     PISSN: 00664227     EISSN: 15453251     Source Type: Book Series    
DOI: 10.1146/annurev-micro-091313-103727     Document Type: Review

References (148)

1. Acharya R, Carnevale V, Fiorin G, Levine BG, Polishchuk AL, et al. 2010. Structure and mechanism of proton transport through the transmembrane tetrameric M2 protein bundle of the influenza A virus. Proc. Natl. Acad. Sci. USA 107:15075-80
2. Adduci AJ, Schlegel R. 1999. The transmembrane domain of the E5 oncoprotein contains functionally discrete helical faces. J. Biol. Chem. 274:10249-58
3. Alix E, Blanc-Potard AB. 2008. Peptide-assisted degradation of the Salmonella MgtC virulence factor. EMBO J. 27:546-57
4. Alix E, Blanc-Potard AB. 2009. Hydrophobic peptides: novel regulators within bacterial membrane. Mol. Microbiol. 72:5-11
5. Arias JF, Iwabu Y, Tokunaga K. 2011. Structural basis for the antiviral activity of BST-2/tetherin and its viral antagonism. Front. Microbiol. 2:250
6. Arias JF, Iwabu Y, Tokunaga K. 2012. Sites of action of HIV-1 Vpu in BST-2/tetherin downregulation. Curr. HIV Res. 10:283-91
7. Balannik V, Carnevale V, Fiorin G, Levine BG, Lamb RA, et al. 2010. Functional studies and modeling of pore-lining residue mutants of the influenza A virus M2 ion channel. Biochemistry 49:696-708
8. Balannik V, Wang J, Ohigashi Y, Jing X, Magavern E, et al. 2009. Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus. Biochemistry 48:11872-82
9. Bao X, Kolli D, LiuT, Shan Y,Garofalo RP, Casola A. 2008. Humanmetapneumovirus small hydrophobic protein inhibits NF-κB transcriptional activity. J. Virol. 82:8224-29
10. Betakova T, Wolffe EJ, Moss B. 2000. The vaccinia virus A14.5L gene encodes a hydrophobic 53- amino-acid virion membrane protein that enhances virulence in mice and is conserved among vertebrate poxviruses. J. Virol. 74:4085-92
11. Binette J, Dube M, Mercier J,HalawaniD, Latterich M, Cohen EA. 2007. Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type 1 Vpu protein in the endoplasmic reticulum. Retrovirology 4:75
12. Bolduan S, Votteler J, Lodermeyer V, Greiner T, Koppensteiner H, et al. 2011. Ion channel activity of HIV-1 Vpu is dispensable for counteraction of CD317. Virology 416:75-85
13. Bruce EA, Medcalf L, Crump CM, Noton SL, Stuart AD, et al. 2009. Budding of filamentous and nonfilamentous influenza A virus occurs via a VPS4 and VPS28-independent pathway. Virology 390:268-78
14. Butticaz C, Michielin O, Wyniger J, Telenti A, Rothenberger S. 2007. Silencing of both β-TrCP1 and HOS (β-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation. J. Virol. 81:1502-5
15. Cady SD, Schmidt-Rohr K, Wang J, Soto CS, Degrado WF, Hong M. 2010. Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature 463:689-92
16. Cammett TJ, Jun SJ, Cohen EB, Barrera FN, Engelman DM, DiMaio D. 2010. Construction and genetic selection of small transmembrane proteins that activate the human erythropoietin receptor. Proc. Natl. Acad. Sci. USA 107:3447-52
17. Chacon KM, Petti LM, Scheideman EH, Pirazzoli V, Politi K, DiMaio D. 2014. De novo selection of oncogenes. Proc. Natl. Acad. Sci. USA 111:E6-14
18. Chen BJ, Lamb RA. 2008. Mechanisms for enveloped virus budding: Can some viruses do without an ESCRT? Virology 372:221-32
19. Chichon FJ, Rodriguez MJ, Risco C, Fraile-Ramos A, Fernandez JJ, et al. 2009. Membrane remodelling during vaccinia virus morphogenesis. Biol. Cell 101:401-14
20. Corteggio A, Altamura G, Roperto F, Borzacchiello G. 2013. Bovine papillomavirus E5 and E7 oncoproteins in naturally occurring tumors: Are two better than one? Infect. Agents Cancer 8:1
21. DiMaio D, Petti LM. 2013. The E5 proteins. Virology 445:99-114
22. Drummond-Barbosa DA, Vaillancourt RR, Kazlauskas A, DiMaio D. 1995. Ligand-independent activation of the platelet-derived growth factor-receptor: requirements for bovine papillomavirus E5-induced mitogenic signaling. Mol. Cell. Biol. 15:2570-81
23. Dube M, Bego MG, Paquay C, Cohen EA. 2010. Modulation of HIV-1-host interaction: role of the Vpu accessory protein. Retrovirology 7:114
24. Dube M, Paquay C, Roy BB, Bego MG,Mercier J, Cohen EA. 2011. HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface. Traffic 12:1714-29
25. Duff KC, Ashley RH. 1992. The transmembrane domain of influenza A M2 protein forms amantadinesensitive proton channels in planar lipid bilayers. Virology 190:485-89
26. Edwards AP, Xie Y, Bowers L, DiMaio D. 2013. Compensatory mutants of the bovine papillomavirus E5 protein and the platelet-derived growth factor σ receptor reveal a complex direct transmembrane interaction. J. Virol. 87:10936-45
27. Edwards D, Fenizia C, Gold H, Fernanda de Castro-Amarante M, Buchmann C, et al. 2011. Orf-I and Orf-II-encoded proteins in HTLV-1 infection and persistence. Viruses 3:861-85
28. Fehrmann F, Klumpp DJ, Laimins LA. 2003. Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation. J. Virol. 77:2819-31
29. Fontaine F, Fuchs RT, Storz G. 2011. Membrane localization of small proteins in Escherichia coli. J. Biol. Chem. 86:32464-74
30. Freeman-Cook L, Dixon AM, Frank JB, Xia Y, Ely L, et al. 2004. Selection and characterization of small random transmembrane proteins that bind and activate the platelet-derived growth factor β receptor. J. Mol. Biol. 338:907-20
31. Freeman-Cook LL, Edwards APB, Dixon AM, Yates KE, Ely L, et al. 2005. Specific locations of hydrophilic amino acids in constructed transmembrane ligands of the platelet-derived growth factor β receptor. J. Mol. Biol. 345:907-21
32. Fuentes S, Tran KC, Luthra P, TengMN, He B. 2007. Function of the respiratory syncytial virus small hydrophobic protein. J. Virol. 81:8361-66
33. Fujita K, Omura S, Silver J. 1997. Rapid degradation ofCD4in cells expressing human immunodeficiency virus type 1 Env and Vpu is blocked by proteasome inhibitors. J. Gen. Virol. 78(Pt. 3):619-25
34. Gan SW, Tan E, Lin X, Yu D, Wang J, et al. 2012. The small hydrophobic protein of the human respiratory syncytial virus forms pentameric ion channels. J. Biol. Chem. 287:24671-89
35. Genther SM, Sterling S, Duensing S, Munger K, Sattler C, Lambert PF. 2003. Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. J. Virol. 77:2832-42
36. Genther-Williams SM, Disbrow GL, Schlegel R, Lee D, Threadgill DW, Lambert PF. 2005. Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. Cancer Res. 65:6534-42
37. Goebel SJ, Johnson GP, Perkus ME, Davis SW, Winslow JP, Paoletti E. 1990. The complete DNA sequence of vaccinia virus. Virology 179:247-66, 517-63
38. Goldstein DJ, Andresson T, Sparkowski JJ, Schlegel R. 1992. The BPV-1 E5 protein, the 16 kDa membrane pore-forming protein and the PDGF receptor exist in a complex that is dependent on hydrophobic transmembrane interactions. EMBO J. 11:4851-59
39. Goldstein DJ, Finbow ME, Andresson T, McLean P, Smith K, et al. 1991. Bovine papillomavirus E5 oncoprotein binds to the 16K component of vacuolar H+-ATPases. Nature 352:347-49
40. Goldstein DJ, Li W, Wang L-M, Heidaran MA, Aaronson SA, et al. 1994. The bovine papillomavirus type 1 E5 transforming protein specifically binds and activates the β-type receptor for platelet-derived growth factor but not other tyrosine kinase-containing receptors to induce cellular transformation. J. Virol. 68:4432-41
41. Habermann A, Krijnse-Locker J, Oberwinkler H, EckhardtM, Homann S, et al. 2010. CD317/tetherin is enriched in the HIV-1 envelope and downregulated from the plasma membrane upon virus infection. J. Virol. 84:4646-58
42. Hay AJ, Wolstenholme AJ, Skehel JJ, SmithMH. 1985. Themolecular basis of the specific anti-influenza action of amantadine. EMBO J. 4:3021-24
43. He B, LeserGP, Paterson RG, LambRA. 1998. The paramyxovirus SV5 small hydrophobic (SH) protein is not essential for virus growth in tissue culture cells. Virology 250:30-40
44. He B, Lin GY, Durbin JE, Durbin RK, Lamb RA. 2001. The SH integral membrane protein of the paramyxovirus simian virus 5 is required to block apoptosis in MDBK cells. J. Virol. 75:4068-79
45. Helenius A. 1992. Unpacking the incoming influenza virus. Cell 69:577-78
46. Hemm MR, Paul BJ, Schneider TD, Storz G, Rudd KE. 2008. Small membrane proteins found by comparative genomics and ribosome binding site models. Mol. Microbiol. 70:1487-501
47. Hobbs EC, Fontaine F, Yin X, Storz G. 2011. An expanding universe of small proteins. Curr. Opin. Microbiol. 14:167-73
48. Holsinger LJ, Lamb RA. 1991. Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology 183:32-43
49. Horwitz BH, Burkhardt AL, Schlegel R, DiMaio D. 1988. 44-amino-acid E5 transforming protein of bovine papillomavirus requires a hydrophobic core and specific carboxyl-terminal amino acids. Mol. Cell. Biol. 8:4071-78
50. HuF, Luo W, Cady SD,HongM. 2011. Conformational plasticity of the influenza AM2 transmembrane helix in lipid bilayers under varying pH, drug binding, and membrane thickness. Biochim. Biophys. Acta 1808:415-23
51. Hu F, Luo W, Hong M. 2010. Mechanisms of proton conduction and gating in influenza M2 proton channels from solid-state NMR. Science 330:505-8
52. Iwabu Y, Fujita H, Kinomoto M, Kaneko K, Ishizaka Y, et al. 2009. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J. Biol. Chem. 284:35060-72
53. Jing X, Ma C, Ohigashi Y, Oliveira FA, Jardetzky TS, et al. 2008. Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc. Natl. Acad. Sci. USA 105:10967-72
54. King G, Oates J, Patel D, van den Berg HA,Dixon AM. 2011. Towards a structural understanding of the smallest known oncoprotein: investigation of the bovine papillomavirus E5 protein using solution-state NMR. Biochim. Biophys. Acta 1808:1493-501
55. Klein O, Kegler-Ebo D, Su J, Smith S, DiMaio D. 1999. The bovine papillomavirus E5 protein requires a juxtamembrane negative charge for activation of the platelet-derived growth factor σ receptor and transformation of C127 cells. J. Virol. 73:3264-72
56. Klein O, Polack GW, Surti T, Kegler-Ebo D, Smith SO, DiMaio D. 1998. Role of glutamine 17 of the bovine papillomavirus E5 protein in platelet-derived growth factor σ receptor activation and cell transformation. J. Virol. 72:8921-32
57. Klimkait T, Strebel K, Hoggan MD, Martin MA, Orenstein JM. 1990. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J. Virol. 64:621-29
58. Kochendoerfer GG, SalomD, Lear JD, Wilk-Orescan R, Kent SB,DeGrado WF. 1999. Total chemical synthesis of the integral membrane protein influenza A virus M2: role of its C-terminal domain in tetramer assembly. Biochemistry 38:11905-13
59. Lai CC, Henningson C, DiMaio D. 1998. Bovine papillomavirus E5 protein induces oligomerization and trans-phosphorylation of the platelet-derived growth factor β receptor. Proc. Natl. Acad. Sci. USA 95:15241-46
60. Leechanachai P, Banks L, Moreau F, Matlashewski G. 1992. The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene 7:19-25
61. Lehnert U, Xia Y, Royce TE,Goh CS, Liu Y, et al. 2004. Computational analysis ofmembrane proteins: genomic occurrence, structure prediction and helix interactions. Q. Rev. Biophys. 37:121-46
62. Leptak C, Ramon Y, Cajal S, Kulke R, Horwitz BH, et al. 1991. Tumorigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16. J. Virol. 65:7078-83
63. Li C, Qin H, Gao FP, Cross TA. 2007. Solid-state NMR characterization of conformational plasticity within the transmembrane domain of the influenza A M2 proton channel. Biochim. Biophys. Acta 1768:3162-70
64. Li Z, Xu J, Patel J, Fuentes S, Lin Y, et al. 2011. Function of the small hydrophobic protein of J paramyxovirus. J. Virol. 85:32-42
65. Lin Y, Bright AC, Rothermel TA, He B. 2003. Induction of apoptosis by paramyxovirus simian virus 5 lacking a small hydrophobic gene. J. Virol. 77:3371-83
66. Ma C, Polishchuk AL, Ohigashi Y, Stouffer AL, Schon A, et al. 2009. Identification of the functional core of the influenza A virus A/M2 proton-selective ion channel. Proc. Natl. Acad. Sci. USA 106:12283-88
67. Mackenzie KR. 2006. Folding and stability of α-helical integral membrane proteins. Chem. Rev. 106:1931-77
68. Magadan JG, Bonifacino JS. 2012. Transmembrane domain determinants of CD4 downregulation by HIV-1 Vpu. J. Virol. 86:757-72
69. Magadan JG, Perez-Victoria FJ, Sougrat R, Ye Y, Strebel K, Bonifacino JS. 2010. Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps. PLoS Pathog. 6:e1000869
70. Margottin F, Bour SP, Durand H, Selig L, Benichou S, et al. 1998. A novel human WD protein, h-βTrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol. Cell 1:565-74
71. Maruri-Avidal L, Domi A,Weisberg AS, Moss B. 2011. Participation of vaccinia virus L2 protein in the formation of crescent membranes and immature virions. J. Virol. 85:2504-11
72. Maruri-Avidal L, Weisberg AS, Moss B. 2013. Direct formation of vaccinia virus membranes from the endoplasmic reticulum in the absence of the newly characterized L2-interacting protein A30.5. J. Virol. 87:12313-26
73. Mattoon D, Gupta K, Doyon J, Loll PJ, DiMaio D. 2001. Identification of the transmembrane dimer interface of the bovine papillomavirus E5 protein. Oncogene 20:3824-34
74. McCown MF, Pekosz A. 2006. Distinct domains of the influenza A virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. J. Virol. 80:8178-89
75. McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana IB, et al. 2009. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog. 5:e1000300
76. Mercer J, Traktman P. 2003. Investigation of structural and functional motifs within the vaccinia virus A14 phosphoprotein, an essential component of the virion membrane. J. Virol. 77:8857-71
77. Meyer AN, Xu Y-F, Webster MK, Smith AS, Donoghue DJ. 1994. Cellular transformation by a transmembrane peptide: structural requirements for the bovine papillomavirus E5 oncoprotein. Proc. Natl. Acad. Sci. USA 91:4634-38
78. Nappi VM, Petti LM. 2002. Multiple transmembrane amino acid requirements suggest a highly specific interaction between the bovine papillomavirus E5 oncoprotein and the platelet-derived growth factor β receptor. J. Virol. 76:7976-86
79. Nappi VM, Schaefer JA, Petti LM. 2002. Molecular examination of the transmembrane requirements of the platelet-derived growth factor-receptor for a productive interaction with the bovine papillomavirus E5 oncoprotein. J. Biol. Chem. 277:47149-59
80. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-30
81. Nichols RJ, Stanitsa E, Unger B, Traktman P. 2008. The vaccinia virus gene I2L encodes a membrane protein with an essential role in virion entry. J. Virol. 82:10247-61
82. Nieva JL, Madan V, Carrasco L. 2012. Viroporins: structure and biological functions. Nat. Rev. Microbiol. 10:563-74
83. Nilson LA, DiMaio D. 1993. Platelet-derived growth factor receptor can mediate tumorigenic transformation by the bovine papillomavirus E5 protein. Mol. Cell. Biol. 13:4137-45
84. Opatowsky Y, Lax I, Tome F, Bleichert F, Unger VM, Schlessinger J. 2014. Structure, domain organization, and different conformational states of stem cell factor-induced intact KIT dimers. Proc. Natl. Acad. Sci. USA 111:1772-77
85. Park SH,Mrse AA, Nevzorov AA, Mesleh MF, Oblatt-Montal M, et al. 2003. Three-dimensional structure of the channel-forming trans-membrane domain of virus protein "u" (Vpu) from HIV-1. J. Mol. Biol. 333:409-24
86. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, et al. 2009. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139:499-511
87. Petti L, DiMaio D. 1992. Stable association between the bovine papillomavirus E5 transforming protein and activated platelet-derived growth factor receptor in transformed mouse cells. Proc. Natl. Acad. Sci. USA 89:6736-40
88. Petti L, DiMaio D. 1994. Specific interaction between the bovine papillomavirusE5 transforming protein and the σ receptor for platelet-derived growth factor in stably transformed and acutely transfected cells. J. Virol. 68:3582-92
89. Petti L, Nilson LA, DiMaio D. 1991. Activation of the platelet-derived growth factor receptor by the bovine papillomavirus E5 transforming protein. EMBO J. 10:845-55
90. Petti LM, Reddy V, Smith SO, DiMaio D. 1997. Identification of amino acids in the transmembrane and juxtamembrane domains of the platelet-derived growth factor receptor required for productive interaction with the bovine papillomavirus E5 protein. J. Virol. 71:7318-27
91. PettiLM,Talbert-Slagle K, HochstrasserML, DiMaio D. 2013.Asingle amino acid substitution converts a transmembrane protein activator of the platelet-derived growth factor β receptor into an inhibitor. J. Biol. Chem. 288:27273-86
92. Pim D, Collins M, Banks L. 1992. Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene 7:27-32
93. Pinto LH, Dieckmann GR, Gandhi CS, Papworth CG, Braman J, et al. 1997. A functionally defined model for the M2 proton channel of influenza A virus suggests a mechanism for its ion selectivity. Proc. Natl. Acad. Sci. USA 94:11301-6
94. Pinto LH, Holsinger LJ, Lamb RA. 1992. Influenza virus M2 protein has ion channel activity. Cell 69:517-28
95. Pinto LH, Lamb RA. 2006. The M2 proton channels of influenza A and B viruses. J. Biol. Chem. 281:8997-9000
96. Pinto LH, Lamb RA. 2007. Controlling influenza virus replication by inhibiting its proton channel. Mol. Biosyst. 3:18-23
97. Popot J-L, Engelman DM. 2000. Helical membrane protein folding, stability, and evolution. Annu. Rev. Biochem. 69:881-922
98. Ptacek JB, Edwards APB, Freeman-Cook LL, DiMaio D. 2007. Packing contacts can mediate highly specific interactions between artificial transmembrane proteins and the PDGFβ receptor. Proc. Natl. Acad. Sci. USA 104:11945-50
99. Raghava S, Giorda KM, Romano FB, Heuck AP, Hebert DN. 2011. The SV40 late protein VP4 is a viroporin that forms pores to disrupt membranes for viral release. PLoS Pathog. 7:e1002116
100. Roberts KL, Leser GP, Ma C, Lamb RA. 2013. The amphipathic helix of influenza A virus M2 protein is required for filamentous bud formation and scission of filamentous and spherical particles. J. Virol. 87:9973-82
101. Rodriguez JR, Risco C, Carrascosa JL, Esteban M, Rodriguez D. 1998. Vaccinia virus 15-kilodalton (A14L) protein is essential for assembly and attachment of viral crescents to virosomes. J. Virol. 72:1287-96
102. Rossman JS, Jing X, Leser GP, Lamb RA. 2010. Influenza virus M2 protein mediates ESCRTindependent membrane scission. Cell 142:902-13
103. Satheshkumar PS, Chavre J, Moss B. 2013. Role of the vaccinia virus O3 protein in cell entry can be fulfilled by its Sequence flexible transmembrane domain. Virology 444:148-57
104. Satheshkumar PS, Moss B. 2009. Characterization of a newly identified 35-amino-acid component of the vaccinia virus entry/fusion complex conserved in all chordopoxviruses. J. Virol. 83:12822-32
105. Satheshkumar PS,Moss B. 2012. Sequence-divergent chordopoxvirus homologs of theO3 protein maintain functional interactions with components of the vaccinia virus entry-fusion complex. J. Virol. 86:1696-705
106. Scheideman EH, Marlatt SA, Xie Y, Hu Y, Sutton RE, DiMaio D. 2012. Transmembrane protein aptamers that inhibit CCR5 expression and HIV coreceptor function. J. Virol. 86:10281-92
107. Schlegel R, Wade-Glass M, Rabson MS, Yang YC. 1986. The E5 transforming gene of bovine papillomavirus encodes a small, hydrophobic polypeptide. Science 233:464-67
108. Schneider D. 2004. Rendezvous in a membrane: close packing, hydrogen bonding, and the formation of transmembrane helix oligomers. FEBS Lett. 577:5-8
109. Schneider D, Finger C, Prodohl A, Volkmer T. 2007. From interactions of single transmembrane helices to folding of α-helical membrane proteins: analyzing transmembrane helix-helix interactions in bacteria. Curr. Protein Pept. Sci. 8:45-61
110. Schnell JR, Chou JJ. 2008. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 451:591-95
111. Schubert U, Anton LC, Bacik I, Cox JH, Bour S, et al. 1998. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J. Virol. 72:2280-88
112. Schubert U, Ferrer-Montiel AV, Oblatt-Montal M, Henklein P, Strebel K,MontalM. 1996. Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. FEBS Lett. 398:12-18
113. Shim AH, Liu H, Focia PJ, Chen X, Lin PC, He X. 2010. Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex. Proc. Natl. Acad. Sci. USA 107:11307-12
114. Skasko M, Wang Y, Tian Y, Tokarev A, Munguia J, et al. 2012. HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions. J. Biol. Chem. 287:58-67
115. Sood CL, Ward JM, Moss B. 2008. Vaccinia virus encodes I5, a small hydrophobic virion membrane protein that enhances replication and virulence in mice. J. Virol. 82:10071-78
116. Staebler A, Pierce JH, Brazinski S, Heidaran MA, Li W, et al. 1995. Mutational analysis of the β-type platelet-derived growth factor receptor defines the site of interaction with the bovine papillomavirus type 1 E5 transforming protein. J. Virol. 69:6507-17
117. Stern-Ginossar N, Weisburd B, Michalski A, Le VT, Hein MY, et al. 2012. Decoding human cytomegalovirus. Science 338:1088-93
118. StoufferAL,MaC, Cristian L, Ohigashi Y, Lamb RA, et al. 2008. The interplay of functional tuning, drug resistance, and thermodynamic stability in the evolution of theM2 proton channel from the influenza A virus. Structure 16:1067-76
119. Straight SW, Herman B, McCance DJ. 1995. The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. J. Virol. 69:3185-92
120. Straight SW, Hinkle PM, Jewers RJ,McCance DJ. 1993. The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes. J. Virol. 67:4521-32
121. Strebel K, Klimkait T, Martin MA. 1988. A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 241:1221-23
122. Sugrue RJ, Hay AJ. 1991. Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology 180:617-24
123. Surti T, Klein O, Aschheim K, DiMaio D, Smith SO. 1998. Structural models of the bovine papillomavirus E5 protein. Proteins 33:601-12
124. Suzuki H, Saito R, Masuda H, Oshitani H, Sato M, Sato I. 2003. Emergence of amantadine-resistant influenza A viruses: epidemiological study. J. Infect. Chemother. 9:195-200
125. Suzuki T, Orba Y, Okada Y, Sunden Y, Kimura T, et al. 2010. The human polyoma JC virus agnoprotein acts as a viroporin. PLoS Pathog. 6:e1000801
126. Takeuchi K, TanabayashiK,Hishiyama M, Yamada A. 1996. Themumps virus SHprotein is amembrane protein and not essential for virus growth. Virology 225:156-62
127. Talbert-Slagle K, Marlatt S, Barrera FN, Khurana E, Oates J, et al. 2009. Artificial transmembrane oncoproteins smaller than the bovine papillomavirus E5 protein redefine the sequence requirements for activation of the platelet-derived growth factor β receptor. J. Virol. 83:9773-85
128. Terwilliger EF, Cohen EA, Lu YC, Sodroski JG, Haseltine WA. 1989. Functional role of human immunodeficiency virus type 1 vpu. Proc. Natl. Acad. Sci. USA 86:5163-67
129. Traktman P, Liu K, DeMasi J, Rollins R, Jesty S, Unger B. 2000. Elucidating the essential role of the A14 phosphoprotein in vaccinia virusmorphogenesis: construction and characterization of a tetracyclineinducible recombinant. J. Virol. 74:3682-95
130. Unger B, Mercer J, Boyle KA, Traktman P. 2013. Biogenesis of the vaccinia virus membrane: genetic and ultrastructural analysis of the contributions of the A14 and A17 proteins. J. Virol. 87:1083-97
131. Unger B, Nichols RJ, Stanitsa ES, Traktman P. 2008. Functional characterization of the vaccinia virus I5 protein. Virol. J. 5:148
132. Unger B, Traktman P. 2004. Vaccinia virusmorphogenesis: A13 phosphoprotein is required for assembly of mature virions. J. Virol. 78:8885-901
133. VanDamme N, Goff D, KatsuraC, Jorgenson RL, Mitchell R, et al. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-52
134. Venkataraman P, Lamb RA, Pinto LH. 2005. Chemical rescue of histidine selectivity filter mutants of the M2 ion channel of influenza A virus. J. Biol. Chem. 280:21463-72
135. Votteler J, Sundquist WI. 2013. Virus budding and the ESCRT pathway. Cell Host Microbe 14:232-41
136. Wang C, Lamb RA, Pinto LH. 1995. Activation of the M2 ion channel of influenza virus: a role for the transmembrane domain histidine residue. Biophys. J. 69:1363-71
137. Wang J, Ma C, Balannik V, Pinto LH, Lamb RA, DegradoWF. 2011. Exploring the requirements for the hydrophobic scaffold and polar amine in inhibitors of M2 from influenza A virus. ACS Med. Chem. Lett. 2:307-12
138. Wang J, Ma C, Fiorin G, Carnevale V, Wang T, et al. 2011. Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2. J. Am. Chem. Soc. 133:12834-41
139. Wang J, Pielak RM, McClintock MA, Chou JJ. 2009. Solution structure and functional analysis of the influenza B proton channel. Nat. Struct. Mol. Biol. 16:1267-71
140. Wang J, Qiu JX, Soto C, DeGradoWF. 2011. Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus. Curr. Opin. Struct. Biol. 21:68-80
141. Watanabe S, Watanabe T, Kawaoka Y. 2009. Influenza A virus lacking M2 protein as a live attenuated vaccine. J. Virol. 83:5947-50
142. Watanabe T, Watanabe S, Ito H, Kida H, Kawaoka Y. 2001. Influenza A virus can undergo multiple cycles of replication without M2 ion channel activity. J. Virol. 75:5656-62
143. Watanabe T, Watanabe S, Kim JH, Hatta M, Kawaoka Y. 2008. Novel approach to the development of effective H5N1 influenza A virus vaccines: use of M2 cytoplasmic tail mutants. J. Virol. 82:2486-92
144. Wetherill LF, Holmes KK, Verow M, Muller M, Howell G, et al. 2012. High-risk human papillomavirus E5 oncoprotein displays channel-forming activity sensitive to small-molecule inhibitors. J. Virol. 86:5341-51
145. Wilson RL, Fuentes SM,Wang P,Taddeo EC, Klatt A, et al. 2006. Function of small hydrophobic proteins of paramyxovirus. J. Virol. 80:1700-9
146. Windisch D, Hoffmann S, Afonin S, Vollmer S, Benamira S, et al. 2010. Structural role of the conserved cysteines in the dimerization of the viral transmembrane oncoprotein E5. Biophys. J. 99:1764-72
147. Yang X, Tschaplinski TJ, Hurst GB, Jawdy S, Abraham PE, et al. 2011. Discovery and annotation of small proteins using genomics, proteomics, and computational approaches. Genome Res. 21:634-41
148. Yuzawa S,Opatowsky Y, Zhang Z,MandiyanV, Lax I, Schlessinger J. 2007. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 130:323-34